Diversified and disruptive: growth investing in a changing world

Spencer Adair



Important information and risk factors

This presentation has been prepared for use by professional advisers and intermediaries only. It is not intended for use by retail clients.

This is a marketing communication and should not be considered as advice or a recommendation to buy, sell or hold a particular investment. This document contains information on investments which does not constitute independent investment research. Accordingly, it is not subject to the protections afforded to independent research and Baillie Gifford and its staff may have dealt in the investments concerned. Investment markets and conditions can change rapidly and as such the views expressed should not be taken as statements of fact nor should reliance be placed on these views when making investment decisions.

Baillie Gifford & Co Limited is authorised and regulated by the Financial Conduct Authority. Baillie Gifford & Co Limited is the authorised Alternative Investment Fund Manager and Company Secretary of the Trust.

The Monks Investment Trust is a listed UK company, and is not authorised or regulated by the Financial Conduct Authority. The value of its shares, and any income from them, can fall as well as rise and investors may not get back the amount invested. A Key Information Document for the Trust is available by contacting us.

The specific risks associated with the funds include:

 The Trust invests in overseas securities, changes in the rates of exchange may also cause the value of your investment (and any income it may pay) to go down or up.

Baillie Gifford & Co Limited Calton Square, 1 Greenside Row, Edinburgh EH1 3AN Telephone 0800 917 4752 Fax: 0131 275 3955 bailliegifford.com/intermediaries

Your call may be recorded for training or monitoring purposes.

- Market values for securities which have become difficult to trade may not be readily available, and there can be no assurance that any value assigned to such securities will accurately reflect the price the Trust might receive upon their sale.
- The Trust invests in emerging markets where difficulties in dealing, settlement and custody could arise, resulting in a negative impact on the value of your investment.
- The Monks Investment Trust can borrow money to make further investments (sometimes known as "gearing" or "leverage"). The risk is that when this money is repaid by the Trust, the value of the investments may not be enough to cover the borrowing and interest costs, and the Trust will make a loss. If the Trust's investments fall in value, any borrowings will increase the amount of this loss.
- The Trust can make use of derivatives. The use of derivatives may impact on its performance.
- The aim of the Trust is to achieve capital growth. You should not expect a significant, or steady, annual income from the Trust.

The information and opinions expressed within this presentation are subject to change without notice. This information has been issued and approved by Baillie Gifford & Co Ltd and does not in any way constitute investment advice. This presentation does not constitute an offer or invitation to deal in securities.

All data is source Baillie Gifford & Co unless otherwise stated. Past performance is not a guide to future returns.

Change is accelerating

Broadening disruption of inert sectors

Profound long-term implications for healthcare, finance and law enforcement

Monks is reward seeking – embraces change



How do we harness this?



Sources: © Broadridge, © Spotify, © Martin Marietta Materials Company.

Big winners across the growth spectrum



Source: StatPro, Top 10 stock returns for the Global Alpha Composite from inception (31 May 2005) to 31 March 2022, sterling. Some stocks may not have been held for the whole period.

Baillie Gifford. Diversified and disruptive: growth investing in a changing world.

The headline grabbers



Sources: © Justin Pritchard/AP/REX/Shutterstock, © Bloomberg/GettyImages.

Baillie Gifford. Diversified and disruptive: growth investing in a changing world.

The unheralded growers

Mastercard





Atlas Copco

Sources: © Atlas Copco.

Baillie Gifford. Diversified and disruptive: growth investing in a changing world.

Tomorrow's winners?



Sources: © Bloomberg/GettyImages, © Axon.

Baillie Gifford. Diversified and disruptive: growth investing in a changing world.

Where next?



THE GREAT ENERGY TRANSITION

BIOLOGY-AS-A-SERVICE

Baillie Gifford. Diversified and disruptive: growth investing in a changing world.

Change drives growth

Change underpins technological and societal progress

Monks harnesses this in a diversified portfolio of global companies

Reward seeking and optimistic about the future

Thank you

Monks portfolio

~2.0% Al Mi S	lphabet /licrosoft	AJ Gallagher Pernod Ricard AIA Mastercard	The Schiehallion Fund Li Reliance Industries Prosus	imited		Martin Marietta Materials		
ln'	nternational	Madoroara	Amazon.com Tesla Inc			BHP Group Ryanair TSMC Rio Tinto CRH		42.8%
~1.0% CI Es	Thermo Fisher Scientific Nympus	Meta Platforms Broadridge Financial Solutions Sysmex Adobe Systems	The Trade Desk SEA Limited Moderna Cloudflare Illumina	HDFC Shopify Alibaba Alnylam Pharmaceuticals Ping An Insurance	MercadoLibre DoorDash Meituan Schibsted	CBRE Group Inc Albemarle Booking Holdings Markel Charles Schwab	Teradyne Richemont SiteOne Landscape Supply Atlas Copco SMC	32.0%
Cc Ar Ce Tc Cł	didas SoStar nalog Devices Sertara opicus.com Shewy łoshizaki Corp		Twilio Axon Enterprise ByteDance Naspers Farfetch Li Auto Epic Games Snowflake Genmab Abiomed B3 CyberAgent Datadog Adyen Netflix	Trupanion ICICI Prudential Life Insurance Denali Therapeutics M3 Lemonade Coupang Wayfair Spotify Renishaw STAAR Surgical Adevinta Teladoc Novocure Oscar Health Bumble	Exact Sciences Chegg Carvana Ant International Ubisoft Entertainment Peloton Stripe Space Exploration Technologies Oatly Tencent Music Entertainment Group Vimeo Sensyne Health KE Holdings VK	Epiroc Deutsche Boerse DENSO Howard Hughes Nexans Wizz Air IAC Sands China Brilliance China Automot Silk Invest Africa Food Fo Royalty Pharma		22.9%

As at 31 March 2022. Cash: 2.3%. Figures may not sum due to rounding.

Please note the fund information contained within this report is confidential, proprietary information and should be maintained as such and not disseminated. The content is intended for information purposes only and should not be disclosed to other third parties or used for the purposes of market timing or seeking to gain an unfair advantage.

Baillie Gifford. Diversified and disruptive: growth investing in a changing world.

Annual discrete performance and legal notice

Annual discrete performance – net of fees

Global Alpha	31/03/17– 31/03/18	31/03/18– 31/03/19	31/03/19– 31/03/20	31/03/20– 31/03/21	31/03/21– 31/03/22
Composite (%)	12.6	8.8	-1.6	55.5	-7.1
Index (%)	2.9	11.1	-6.2	39.6	12.9

Source: StatPro, MSCI. Sterling. Index: MSCI ACWI Index

Legal notice

All information is current and sourced from Baillie Gifford & Co unless otherwise stated.

MSCI

Source: MSCI. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indexes or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.